Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Australian Clinical Labs Ltd ( (AU:ACL) ) has shared an update.
Australian Clinical Labs Limited announced its financial results for the first half of the fiscal year 2025, reporting a 9.5% revenue growth and a 9.7% increase in MBS revenue, resulting in an underlying EBIT of $27.3 million. The company reaffirmed its FY25 guidance of $65 million to $73 million and declared a 3.5 cents per share fully franked interim dividend. ACL’s statutory EBIT rose to $26.9 million, up $11.0 million from the previous year, with a statutory NPAT of $11.8 million, reflecting a $6.8 million increase. The company continues its on-market buy-back program, indicating a strong financial performance and commitment to returning value to shareholders.
More about Australian Clinical Labs Ltd
Australian Clinical Labs (ACL) is a leading private provider of pathology services in Australia. The company operates NATA accredited laboratories that conduct a wide range of pathology tests for clients such as doctors, specialists, patients, hospitals, and corporate entities. ACL is one of the largest private hospital pathology businesses in the nation, focusing on combining skilled personnel and scientific leadership with innovative technologies to enhance decision-making and improve patient outcomes.
YTD Price Performance: 7.56%
Average Trading Volume: 477,848
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$742.1M
Learn more about ACL stock on TipRanks’ Stock Analysis page.